Low-grade intra-articular inflammation promotes symptoms and disease progression in osteoarthritis (OA). The multiligand Receptor for Advanced Glycation Endproducts (RAGE) is implicated in several extraskeletal degenerative disorders linked to low-grade tissue inflammation and aging, including diabetes mellitus and Alzheimer's Disease. RAGE ligands include calgranulin/S100 proteins that can exert inflammatory cytokine-like effects. Articular chondrocytes express RAGE, and expression of RAGE and S100A11 are up-regulated in OA cartilage. S100A11 induces chondrocyte hypertrophy. Moreover, CXCL8 and TNFa induce S100A11 expression and chondrocyte hypertrophy, and S100A11-, CXCL8-, and TNFa-induced chondrocyte hypertrophy are RAGE-dependent. Our objective is to define how the prototypical chondrocyte calgranulin S100A11 modulates chondrocyte differentiation and function in vitro via RAGE signaling, and to define the role of RAGE in pathogenesis of OA in vivo. We specifically aim to: 1) Define the molecular structural requirements by which S100A11 modulates chondrocyte differentiation and function. We will test the hypothesis that S100A11 induces hypertrophic differentiation, MMP-13 and ADAMts5 expression, and proteoglycans loss in chondrocytes in a manner that requires one or both S100A11 calcium binding EF hands, as well as multimerization by transglutaminase 2 (TG2). 2) Define the mechanism by RAGE signaling transduces S100A11 effects on chondrocyte differentiation and function. We will test the hypothesis that S100A11 induces RAGE-specific signaling that promotes Rac1 and PI3K signaling upstream to MKK3 and p38 MARK activation, followed by essential downstream HDAC4 depletion to induce terminal hypertrophic chondrocyte differentiation. 3) Test the hypothesis that S100A11 and RAGE directly mediate the pathogenesis of murine OA in vivo by assessing OA severity in a knee instability model in RAGE-/- vs. congenic RAGE+/+ mice. Also, we will test RAGE-/- mouse femoral head cartilage explants for reduced S100A11 and inflammatory cytokine-induced MMP-13 and ADAMts5 expression, chondrocyte hypertrophy, and proteoglycans loss relative to RAGE+/+ explants ex vivo. Completion of the work will reveal new potential targets for therapeutic intervention in OA by disconnecting inflammation from deleterious alteration of chondrocyte differentiation and function. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR054135-03
Application #
7433195
Study Section
Skeletal Biology Structure and Regeneration Study Section (SBSR)
Program Officer
Tyree, Bernadette
Project Start
2006-06-01
Project End
2010-05-31
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
3
Fiscal Year
2008
Total Cost
$232,125
Indirect Cost
Name
Veterans Medical Research Fdn/San Diego
Department
Type
DUNS #
933863508
City
San Diego
State
CA
Country
United States
Zip Code
92161
Petursson, Freyr; Husa, Matt; June, Ron et al. (2013) Linked decreases in liver kinase B1 and AMP-activated protein kinase activity modulate matrix catabolic responses to biomechanical injury in chondrocytes. Arthritis Res Ther 15:R77
Terkeltaub, Robert; Yang, Bing; Lotz, Martin et al. (2011) Chondrocyte AMP-activated protein kinase activity suppresses matrix degradation responses to proinflammatory cytokines interleukin-1? and tumor necrosis factor ?. Arthritis Rheum 63:1928-37
Liu-Bryan, Ru; Terkeltaub, Robert (2010) Chondrocyte innate immune myeloid differentiation factor 88-dependent signaling drives procatabolic effects of the endogenous Toll-like receptor 2/Toll-like receptor 4 ligands low molecular weight hyaluronan and high mobility group box chromosomal protein Arthritis Rheum 62:2004-12
Lotz, Martin K; Otsuki, Shuhei; Grogan, Shawn P et al. (2010) Cartilage cell clusters. Arthritis Rheum 62:2206-18
Cecil, Denise L; Appleton, C Thomas G; Polewski, Monika D et al. (2009) The pattern recognition receptor CD36 is a chondrocyte hypertrophy marker associated with suppression of catabolic responses and promotion of repair responses to inflammatory stimuli. J Immunol 182:5024-31
Huebner, J L; Johnson, K A; Kraus, V B et al. (2009) Transglutaminase 2 is a marker of chondrocyte hypertrophy and osteoarthritis severity in the Hartley guinea pig model of knee OA. Osteoarthritis Cartilage 17:1056-64
Cecil, Denise L; Terkeltaub, Robert (2008) Transamidation by transglutaminase 2 transforms S100A11 calgranulin into a procatabolic cytokine for chondrocytes. J Immunol 180:8378-85
Johnson, Kristen A; Rose, David M; Terkeltaub, Robert A (2008) Factor XIIIA mobilizes transglutaminase 2 to induce chondrocyte hypertrophic differentiation. J Cell Sci 121:2256-64
Johnson, Kristen A; Polewski, Monika; Terkeltaub, Robert A (2008) Transglutaminase 2 is central to induction of the arterial calcification program by smooth muscle cells. Circ Res 102:529-37